Workflow
Castle Biosciences, Inc. (CSTL) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates
CSTLCastle Biosciences(CSTL) Zacks Investment Research·2024-02-29 00:31

Castle Biosciences, Inc. (CSTL) reported 66.12millioninrevenueforthequarterendedDecember2023,representingayear−over−yearincreaseof72.566.12 million in revenue for the quarter ended December 2023, representing a year-over-year increase of 72.5%. EPS of -0.10 for the same period compares to -0.78ayearago.ThereportedrevenuecomparestotheZacksConsensusEstimateof0.78 a year ago.The reported revenue compares to the Zacks Consensus Estimate of 51.32 million, representing a surprise of +28.85%. The company delivered an EPS surprise of +88.10%, with the consensus EPS estimate being -$0.84.While investors scrutinize revenue and earnings changes year-over-year and how they ...